This is read by an automated voice. Please report any issues or inconsistencies here. U.S. regulators this week gave the green light to a pill version of the ...

Dec. 30, 2025 – updated Jan. 5, 2026 – Injectable GLP-1 drugs have transformed obesity treatment – and now they're going oral. "It's good to have more options for patients with obesity," said Melanie ...

The new Wegovy pill was just approved in the US—and it’s the first oral GLP-1 for weight management on the market. Trials suggest it’s approximately as effective as the injectable form, and it has ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including Wegovy and Zepbound are expected to be easier to access and afford. And new ...

The U.S. Food and Drug Administration-approved Wegovy pill will be here before you'd think. Fresh off winning approval from the FDA in December, Wegovy manufacturer Novo Nordisk says it will have the ...

LONDON, Dec 29 (Reuters) - Ask executives in the healthcare industry about the future market for weight-loss drugs and the analogies are telling: monthly GLP-1 medicine subscriptions like a streaming ...

UnitedHealth Group’s pharmacy mailed Medicare recipient Bill Zielinski so many refills of the cholesterol drug atorvastatin that his unused stash could last a year on the pill-a-day regimen his doctor ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk plans to ...

The Food and Drug Administration has approved Novo Nordisk’s once-daily Wegovy pill, the first oral GLP-1 medicine for obesity in the United States. The full launch of the pill is expected in January.

MORE AMERICANS THAN EVER are taking weight-loss drugs or considering them. Now, they have a new option. The first GLP-1 oral pill is now available at pharmacies nationwide. The Wegovy pill was ...

Eli Lilly stock was on the outside looking in on Tuesday as shares of Novo Nordisk, its rival in diabetes and weight-loss drugs, soared after the company secured regulatory approval for a weight-loss ...